<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065632</url>
  </required_header>
  <id_info>
    <org_study_id>0056/2021/P/SG/CNER</org_study_id>
    <nct_id>NCT05065632</nct_id>
  </id_info>
  <brief_title>Seroepidemiological Investigation of Coronavirus 2019 (COVID-19) Infection in Gabon</brief_title>
  <acronym>Sero-CoV</acronym>
  <official_title>Population-based Age-stratified Seroepidemiological Investigation of Coronavirus 2019 (COVID-19) Infection in Gabon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche Médicale de Lambaréné</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche Médicale de Lambaréné</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gabon is the 3rd country most affected by COVID-19 behind Cameroon and Democratic Republic of&#xD;
      Congo in Central Africa, with 8860 cases and 54 deaths in critically ill patients, since the&#xD;
      first confirmed case of COVID-19 on the 10th of March 2020 (https://africacdc.org/covid-19/).&#xD;
      Most of the individuals infected by SARS-CoV-2 are asymptomatic and they represent a major&#xD;
      source of viral spread. To date, African countries have been less affected by deaths caused&#xD;
      by the Covid-19 pandemic compared to other countries. It is currently unknown why Africa has&#xD;
      avoided more deaths and appears to not simply be due to a lack of testing, since the overall&#xD;
      death rate has not increased. Better quality data on seroprevalence in different African&#xD;
      regions and proven explanations of the differences between Africa and other continents, are&#xD;
      urgently needed. The aim of this study is to learn about the proportion of people after a&#xD;
      first pic of transmission, who have been exposed to COVID-19 in Gabon by testing for plasma&#xD;
      antibodies to the SARS-CoV-2 virus.&#xD;
&#xD;
      The overall goal of this study is to examine the trend of specific anti-SARS-CoV-2 antibodies&#xD;
      in Gabonese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on its technical capacities (ELISA bench and multiparametric flow cytometer), we will&#xD;
      provide evident data on the immune responses in Covid-19 infected patients. The&#xD;
      quantification of antibodies against SARS-CoV-2 recombinant protein will be done by ELISA&#xD;
      using Wantai ELISA total Ab. Meanwhile, data on clinical status will be recorded and&#xD;
      classified using WHO patient form. Data obtained will be analyzed by a statistician based at&#xD;
      CERMEL using robust models in compliance with the type of data generated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>seroprevelence on SARS-Cov- 2 infection in Gabon</measure>
    <time_frame>4 Months</time_frame>
    <description>assess the specific anti-SARS-CoV-2 antibodies in individuals and for modeling the evolution of the COVID-19 outbreak.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">3455</enrollment>
  <condition>Seroprevalence of SARS-CoV-2 Infection (COVID-19) in Gabon</condition>
  <arm_group>
    <arm_group_label>Groupe 1</arm_group_label>
    <description>[1-15[</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>[15- 30[</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>[30-45[</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>[45-60[</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <description>60+</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Wantai kit Elisa</intervention_name>
    <description>to mesure antibodies against SARSCov-2 recombinant antigen</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Groupe 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 3455 people living in Gabon, aged from 1 year, and above will be stratified by&#xD;
        age and included in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons of both sexes aged one year and older and residing for more than three months&#xD;
             in the study area are eligible to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any person not residing in the locality surveyed or any person residing for less than&#xD;
             three months. Refusal to give informed consent and contraindication to venipuncture&#xD;
             venipuncture.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayola Akim A ADEGNIKA, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche Médicale de Lambaréné</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayola A ADEGNIKA, Ph.D</last_name>
    <phone>+24177406464</phone>
    <email>aadegnika@cermel.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafiou Adamou, Ph.D</last_name>
    <email>adamou.rafiou@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherches Medicales de Lambarene</name>
      <address>
        <city>Lambaréné</city>
        <zip>242</zip>
        <country>Gabon</country>
      </address>
    </facility>
    <contact>
      <last_name>Ayola Akim Adegnika, Ph.D</last_name>
      <email>aadegnika@cermel.org</email>
    </contact>
    <contact_backup>
      <last_name>Maxime Agnandji</last_name>
      <email>agnandjis@yahoo.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Gabon</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

